Although the phenomenon of disgruntled employees “ghosting” (also known as “quiet quitting” or “slow quitting”) their workplaces is rife with financial and ethical impacts for the life cycle of clinical research studies, interdisciplinary solutions for detecting and correcting the behavior offer some peace of mind, according to the creators behind a poster that placed in the top three among those presented at ACRP 2025. 

Clinical trials are typically seen as engines of innovation, but for economically disadvantaged individuals, they can also be a gateway to care—particularly for chronic diseases that are expensive to manage. For those living with gastrointestinal (GI) conditions like ulcerative colitis, Crohn’s disease, nonalcoholic fatty liver disease (NAFLD), or NAFLD’s advanced form, nonalcoholic steatohepatitis (NASH), clinical trials may offer access to diagnostics, treatments, and specialists that would otherwise be out of reach.